Quote | NLS Pharmaceutics Ltd. Warrant (NASDAQ:NLSPW)
Last: | $0.0263 |
---|---|
Change Percent: | 0.0% |
Open: | $0.039 |
Close: | $0.0263 |
High: | $0.039 |
Low: | $0.0263 |
Volume: | 2,000 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | NLS Pharmaceutics Ltd. Warrant (NASDAQ:NLSPW)
ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervo...
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous sy...
Message Board Posts | NLS Pharmaceutics Ltd. Warrant (NASDAQ:NLSPW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
NLS Pharmaceutics Ltd. Warrant Company Name:
NLSPW Stock Symbol:
NASDAQ Market:
ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervo...
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous sy...
The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in neuropharmacological therapies. Medications activating dual OX1R/OX2R target a broader range of mechanisms ...